Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Kanuma (sebelipase alfa) for the Treatment of Lysosomal Acid Lipase Deficiency (LAL-D)

Drug (Brand / Generic)

Kanuma / sebelipase alfa

Company

Alexion Pharmaceuticals

Therapy Class

Enzyme replacement therapy (ERT)

Current Indication

Lysosomal acid lipase deficiency (LAL-D)

Market Sector

Genetics

Development Status

Approved in the US and Europe
Expand

Go Top